SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 94 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $263,000 | -74.4% | 221,071 | -29.9% | 0.00% | – |
Q4 2021 | $1,028,000 | +12.0% | 315,195 | +53.5% | 0.00% | – |
Q3 2021 | $918,000 | -45.4% | 205,303 | -33.5% | 0.00% | -100.0% |
Q2 2021 | $1,682,000 | -36.0% | 308,651 | -12.1% | 0.00% | 0.0% |
Q1 2021 | $2,627,000 | -52.1% | 351,169 | -30.5% | 0.00% | -50.0% |
Q4 2020 | $5,480,000 | +10.1% | 505,079 | -10.3% | 0.00% | 0.0% |
Q3 2020 | $4,976,000 | -17.2% | 562,802 | -0.2% | 0.00% | -33.3% |
Q2 2020 | $6,010,000 | +79.8% | 563,772 | 0.0% | 0.00% | +50.0% |
Q1 2020 | $3,343,000 | -3.5% | 563,772 | +12.4% | 0.00% | +100.0% |
Q4 2019 | $3,466,000 | -29.7% | 501,529 | +5.7% | 0.00% | -50.0% |
Q3 2019 | $4,927,000 | +12.1% | 474,616 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $4,394,000 | +32.3% | 474,616 | +30.6% | 0.00% | +100.0% |
Q1 2019 | $3,322,000 | +144.3% | 363,442 | +48.9% | 0.00% | 0.0% |
Q4 2018 | $1,360,000 | -24.1% | 244,080 | +62.3% | 0.00% | 0.0% |
Q3 2018 | $1,791,000 | – | 150,352 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |